169 related articles for article (PubMed ID: 20103626)
1. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.
Zhang Y; Hansen JK; Xiang L; Kawa S; Onda M; Ho M; Hassan R; Pastan I
Cancer Res; 2010 Feb; 70(3):1082-9. PubMed ID: 20103626
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Zhang Y; Xiang L; Hassan R; Pastan I
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17099-104. PubMed ID: 17940013
[TBL] [Abstract][Full Text] [Related]
3. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
Xiang X; Phung Y; Feng M; Nagashima K; Zhang J; Broaddus VC; Hassan R; Fitzgerald D; Ho M
PLoS One; 2011 Jan; 6(1):e14640. PubMed ID: 21305058
[TBL] [Abstract][Full Text] [Related]
4. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice.
Zhang Y; Xiang L; Hassan R; Paik CH; Carrasquillo JA; Jang BS; Le N; Ho M; Pastan I
Clin Cancer Res; 2006 Aug; 12(15):4695-701. PubMed ID: 16899620
[TBL] [Abstract][Full Text] [Related]
6. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
[TBL] [Abstract][Full Text] [Related]
7. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I
Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Liu XF; Xiang L; FitzGerald DJ; Pastan I
Mol Cancer Ther; 2014 Jan; 13(1):82-9. PubMed ID: 24145282
[TBL] [Abstract][Full Text] [Related]
9. The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
Liu XF; FitzGerald DJ; Pastan I
Cancer Res; 2013 Apr; 73(7):2281-8. PubMed ID: 23348423
[TBL] [Abstract][Full Text] [Related]
10. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
11. SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.
Leshem Y; King EM; Mazor R; Reiter Y; Pastan I
Toxins (Basel); 2018 Nov; 10(11):. PubMed ID: 30441807
[TBL] [Abstract][Full Text] [Related]
12. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
13. Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine.
Liu XF; Wei J; Zhou Q; Molitoris BA; Sandoval R; Kobayashi H; Okada R; Nagaya T; Karim B; Butcher D; Pastan I
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6086-6091. PubMed ID: 32123080
[TBL] [Abstract][Full Text] [Related]
14. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
Hassan R; Williams-Gould J; Steinberg SM; Liewehr DJ; Yokokawa J; Tsang KY; Surawski RJ; Scott T; Camphausen K
Clin Cancer Res; 2006 Aug; 12(16):4983-8. PubMed ID: 16914588
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.
Zhang Y; Chertov O; Zhang J; Hassan R; Pastan I
Cancer Res; 2011 Sep; 71(17):5915-22. PubMed ID: 21775520
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
17. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.
Guillemard V; Nedev HN; Berezov A; Murali R; Saragovi HU
DNA Cell Biol; 2005 Jun; 24(6):350-8. PubMed ID: 15941387
[TBL] [Abstract][Full Text] [Related]
18. Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.
Hollevoet K; Antignani A; Fitzgerald DJ; Pastan I
J Immunother; 2014 Jan; 37(1):8-15. PubMed ID: 24316551
[TBL] [Abstract][Full Text] [Related]
19. Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.
Mattoo AR; Pastan I; Fitzgerald D
PLoS One; 2013; 8(10):e75576. PubMed ID: 24130723
[TBL] [Abstract][Full Text] [Related]
20. Discovery of mesothelin and exploiting it as a target for immunotherapy.
Pastan I; Hassan R
Cancer Res; 2014 Jun; 74(11):2907-12. PubMed ID: 24824231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
